Whitener Capital Management Inc. grew its holdings in Sanofi SA (NYSE:SNY) by 100.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,000 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. Whitener Capital Management Inc.’s holdings in Sanofi were worth $86,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in SNY. Lazard Asset Management LLC boosted its position in shares of Sanofi by 47,594.3% during the first quarter. Lazard Asset Management LLC now owns 2,384,716 shares of the company’s stock worth $105,595,000 after buying an additional 2,379,716 shares during the period. Schafer Cullen Capital Management Inc boosted its position in shares of Sanofi by 106.8% during the second quarter. Schafer Cullen Capital Management Inc now owns 728,871 shares of the company’s stock worth $30,088,000 after buying an additional 376,410 shares during the period. Fisher Asset Management LLC boosted its position in shares of Sanofi by 2.2% during the second quarter. Fisher Asset Management LLC now owns 16,868,423 shares of the company’s stock worth $729,897,000 after buying an additional 367,961 shares during the period. Richard C. Young & CO. LTD. acquired a new position in shares of Sanofi during the first quarter worth about $8,583,000. Finally, FMR LLC boosted its position in shares of Sanofi by 1.9% during the first quarter. FMR LLC now owns 9,233,558 shares of the company’s stock worth $408,862,000 after buying an additional 175,580 shares during the period. Institutional investors own 7.04% of the company’s stock.
NYSE SNY traded up $0.37 during trading hours on Friday, hitting $42.02. 973,000 shares of the company traded hands, compared to its average volume of 1,239,559. The business’s 50-day moving average is $42.20 and its 200-day moving average is $42.61. Sanofi SA has a twelve month low of $40.00 and a twelve month high of $45.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The stock has a market capitalization of $104.90 billion, a price-to-earnings ratio of 13.42, a P/E/G ratio of 2.41 and a beta of 0.67.
SNY has been the subject of several recent research reports. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. UBS Group raised Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $51.00.
In related news, major shareholder Sanofi purchased 93,750 shares of Sanofi stock in a transaction that occurred on Monday, July 22nd. The stock was purchased at an average cost of $16.00 per share, with a total value of $1,500,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.00% of the company’s stock.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: What is a death cross?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.